VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+12.86%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$158M
AUM Growth
-$7.14M
(-4.3%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-13.64%
Top 10 Holdings %
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49
Top Buys
| 1 |
Expedia Group
EXPE
|
$932K |
| 2 |
Prologis
PLD
|
$773K |
| 3 |
Gartner
IT
|
$769K |
| 4 |
Quanta Services
PWR
|
$762K |
| 5 |
Trane Technologies
TT
|
$759K |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$854K |
| 2 |
Arthur J. Gallagher & Co
AJG
|
$778K |
| 3 |
IDEX
IEX
|
$731K |
| 4 |
Tesla
TSLA
|
$719K |
| 5 |
VICI Properties
VICI
|
$715K |
Sector Composition
| 1 | Healthcare | 22.36% |
| 2 | Technology | 15.51% |
| 3 | Financials | 14.54% |
| 4 | Industrials | 9.65% |
| 5 | Energy | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
326
Bicycle Therapeutics
BCYC
$496M
| $112K | 0.07% |
6,172
+2,467
| +67% | +$44.6K |
|
327
Kura Oncology
KURA
$713M
| $111K | 0.07% |
7,747
-877
| -10% | -$12.6K |
|
328
Apogee Therapeutics
APGE
$2.26B
| $111K | 0.07% |
+3,984
| New | +$111K |
|
329
Cullinan Oncology
CGEM
$413M
| $111K | 0.07% |
10,879
+2,475
| +29% | +$25.2K |
|
330
Cogent Biosciences
COGT
$1.82B
| $110K | 0.07% |
18,666
+10,966
| +142% | +$64.5K |
|
331
Allogene Therapeutics
ALLO
$255M
| $110K | 0.07% |
34,163
+14,328
| +72% | +$46K |
|
332
Keros Therapeutics
KROS
$633M
| $109K | 0.07% |
2,743
+182
| +7% | +$7.24K |
|
333
Neumora Therapeutics
NMRA
$272M
| $108K | 0.07% |
+6,328
| New | +$108K |
|
334
Nurix Therapeutics
NRIX
$758M
| $107K | 0.07% |
10,356
+1,345
| +15% | +$13.9K |
|
335
Arvinas
ARVN
$575M
| $107K | 0.07% |
2,595
-766
| -23% | -$31.5K |
|
336
Zymeworks
ZYME
$1.14B
| $107K | 0.07% |
10,264
-1,607
| -14% | -$16.7K |
|
337
Olema Pharmaceuticals
OLMA
$570M
| $105K | 0.07% |
+7,515
| New | +$105K |
|
338
Biohaven
BHVN
$1.68B
| $105K | 0.07% |
2,459
-1,598
| -39% | -$68.4K |
|
|
CMPS
339
Compass Pathways
CMPS
$493M
| $105K | 0.07% |
11,992
-557
| -4% | -$4.87K |
|
340
ALX Oncology
ALXO
$65.3M
| $105K | 0.07% |
7,019
-3,708
| -35% | -$55.2K |
|
341
Avidity Biosciences
RNA
$6.48B
| $104K | 0.07% |
11,529
+3,416
| +42% | +$30.9K |
|
342
Viridian Therapeutics
VRDN
$1.53B
| $104K | 0.07% |
4,787
+1,215
| +34% | +$26.5K |
|
343
Dyne Therapeutics
DYN
$2.02B
| $104K | 0.07% |
7,833
-139
| -2% | -$1.85K |
|
344
AnaptysBio
ANAB
$613M
| $104K | 0.07% |
4,862
-461
| -9% | -$9.88K |
|
345
Arcturus Therapeutics
ARCT
$485M
| $104K | 0.07% |
3,302
-280
| -8% | -$8.83K |
|
346
Xenon Pharmaceuticals
XENE
$3.02B
| $103K | 0.07% |
2,245
-79
| -3% | -$3.64K |
|
347
Relay Therapeutics
RLAY
$710M
| $102K | 0.07% |
9,295
+1,023
| +12% | +$11.3K |
|
348
Cabaletta Bio
CABA
$155M
| $102K | 0.06% |
+4,507
| New | +$102K |
|
349
Protagonist Therapeutics
PTGX
$3.77B
| $102K | 0.06% |
4,457
+1,017
| +30% | +$23.3K |
|
350
Celldex Therapeutics
CLDX
$1.52B
| $102K | 0.06% |
2,561
-70
| -3% | -$2.78K |
|